ArticleJournal of nanobiotechnology2025
In vivo dynamic monitoring of self-assembled melatonin nanodrug combined with photothermal effects to alleviate hypoxia to attenuate tumor aggressiveness.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A malignant symbiosis: The neuro-metabolic symphony rewires the tumor microenvironment.Neoplasia (New York, N.Y.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTumor biophysics is characterized by a fundamental aspect known as hypoxia. Melatonin (MLT) can decrease the activity of hypoxia-inducible factors (HIFs), thereby preventing tumor cell survival, proliferation, invasion, metastasis, angiogenesis, and energy metabolism.
resultsTo monitor bioluminescence and assess the ability of combined MLT and photothermal therapy (PTT) to alleviate hypoxia, we constructed a modified A549-HRE-Luc cell line that responded to hypoxia. A versatile nanocarrier was developed to encapsulate MLT and combine near-infrared (NIR)-II fluorescence imaging, magnetic resonance (MR) imaging, and PTT, to effectively suppress tumor HIFs. The therapeutic effects of MLT on HIF-1α and PTT-mediated alleviation of tumor hypoxia were assessed via bioluminescence, which was contributed by the luciferase reporter gene in vivo. Additionally, it demonstrated the capability of NIR-II fluorescence imaging and T
conclusionsUltimately, the findings from both in vitro and in vivo experiments demonstrated that the simultaneous use of MLT and PTT could effectively suppress hypoxia in tumors and trigger programmed apoptosis. As a result, this approach holds promise as a potential combined therapeutic option with enhanced therapeutic effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.